Comment: Is 3,4-DAP a new option in treating MuSK MG?
نویسنده
چکیده
منابع مشابه
Thymolipoma-associated Myasthenia Gravis with High Titer of Anti-MuSKAb: A Case Report
Myasthenia Gravis (MG) is a neuromuscular junction disorder caused by pathogenic autoantibodies to some parts of the post-synaptic muscle endplates. About 85% of generalized MG patients have autoantibodies against post-synaptic acetyl-choline receptors (AChR). From the 10-15% of the remaining patients, 45-50% are positive for Muscle Specific Tyrosine Kinase-Antibody (MuSK-Ab). It is believed th...
متن کاملLong-lasting treatment effect of rituximab in MuSK myasthenia.
OBJECTIVE Rituximab has emerged as an efficacious option for drug-resistant myasthenia gravis (MG). However, reports published only describe the short-term follow-up of patients treated and little is known about their long-term clinical and immunologic evolution. Our objective was to report the clinical and immunologic long-term follow-up of 17 patients (6 MuSK+MG and 11 AChR+MG) and compare th...
متن کاملMaintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.
BACKGROUND Anti-muscle specific kinase antibody positive myasthenia gravis (MuSK MG) is often characterized by a relatively severe and progressive course, refractoriness to standard myasthenia gravis (MG) medications, and an increased risk of myasthenic crisis. We report here successful management of three MuSK MG patients using maintenance therapeutic plasma exchange (TPE) treatment for up to ...
متن کاملNovel drug of choice in Eaton-Lambert syndrome.
Sir: Muscle weakness in the myasthenic syndrome of Eaton-Lambert' is caused by diminished transmitter release from motor nerve endings2 secondary to morphological destruction of the active release zones in the nerve terminals3 which is thought to have an autoimmune aetiology."5 Immunosuppressive therapy has recently been recommended5 but its full effect is delayed by several months and severe s...
متن کاملGuidelines for treatment of autoimmune neuromuscular transmission disorders.
BACKGROUND Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) and neuromyotonia (Isaacs' syndrome). METHODS To prepare consensus guidelines for the treatment of the autoimmune NMT disorders, references retrieved from MEDLINE, EMBASE and the Cochrane Library were co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Neurology
دوره 86 11 شماره
صفحات -
تاریخ انتشار 2016